Tirzepatide 20mg – Dual AgonistResearch Peptide | Tides Lab

Tirzepatide is a synthetic dual agonist peptide targeting the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, representing a significant advancement in incretin-based metabolic research. It has been extensively studied in preclinical and clinical research contexts examining insulin secretion, energy homeostasis, and adipose tissue regulation, and is one of the most widely referenced compounds in contemporary metabolic peptide research literature.

This 20mg lyophilised formulation is supplied at ≥99% purity and intended strictly for laboratory research purposes.

Key Features

• 20mg lyophilised Tirzepatide
• Dual receptor agonist (GLP-1 / GIP) studied in metabolic signalling research
• Investigated in insulin secretion, energy homeostasis and adipose tissue models
• ≥99% purity
• Research use only
• Fast Australian shipping

Mechanism Overview

Tirzepatide is a 39-amino acid synthetic peptide engineered as a single molecule with dual agonist activity at both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). This dual incretin receptor engagement differentiates Tirzepatide from single GLP-1 receptor agonists and has been a primary focus of metabolic research investigating synergistic incretin signalling.

At the GLP-1 receptor, Tirzepatide's studied activity in research models includes glucose-dependent stimulation of insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, and delayed gastric emptying — mechanisms well characterised across GLP-1 receptor agonist research literature. GLP-1R activation has also been studied in the context of hypothalamic satiety signalling, with research describing downstream effects on appetite-regulating neuropeptide pathways in CNS models.

GIP receptor agonism adds a distinct and complementary dimension to Tirzepatide's research profile. In contrast to GLP-1R, GIPR is expressed in adipose tissue as well as pancreatic beta cells, and research has investigated GIPR activation in the context of lipid metabolism, adipocyte function, and energy storage regulation. The combination of GLP-1R and GIPR co-activation in experimental models has been associated with additive or synergistic effects on insulin sensitivity and body composition parameters compared to GLP-1R agonism alone, which has driven significant research interest in dual incretin compounds.

Tirzepatide's molecular structure incorporates a fatty acid chain enabling albumin binding, extending its half-life in experimental models and supporting its use in longer-duration in vivo research protocols. This pharmacokinetic characteristic distinguishes it from shorter-acting incretin analogues and is relevant to study design in metabolic research contexts.

Stability and Handling

Tirzepatide is supplied in lyophilised (freeze-dried) form to preserve peptide stability during storage and transport.

Standard laboratory handling considerations include:

• Refrigerated storage following reconstitution
• Protection from direct light exposure
• Avoiding repeated temperature fluctuations

Research Use Only

Tirzepatide is supplied strictly for laboratory research and educational purposes. It is not approved for therapeutic use and is not intended for human consumption.